You are using an older browser version. Please use a supported version for the best MSN experience.

Teva Donating More Than 10 Million Doses of Hydroxychloroquine as Potential COVID-19 Treatment

The Motley Fool logo The Motley Fool 3/20/2020 Brian Orelli
Teva Donating More Than 10 Million Doses of Hydroxychloroquine as Potential COVID-19 Treatment © Provided by The Motley Fool Teva Donating More Than 10 Million Doses of Hydroxychloroquine as Potential COVID-19 Treatment

Teva Pharmaceutical (NYSE: TEVA) plans to donate 10 million tablets of the malaria drug hydroxychloroquine sulfate as a potential treatment for COVID-19. That news follows a report from earlier this week that Bayer (OTC: BAYRY) plans to donate 3 million tablets of the related drug chloroquine, which is more potent but has more hazardous side effects.

Teva has 6 million tablets on hand, which it plans to ship through wholesalers to hospitals by March 31, with the remaining doses expected to be ready within a month.

Hydroxychloroquine and chloroquine are best-known as treatments for malaria, which is caused by a parasite, not a virus. Hydroxychloroquine is also prescribed for autoimmune diseases. But recent studies reported on in the journal Nature have found both drugs inhibit the ability of the SARS-CoV-2 coronavirus to replicate in the laboratory. How well the drug might  do to help humans fight off the disease is still unknown, although initial reports have been positive.

On Thursday, Mylan (NASDAQ: MYL) said it restarted production of its hydroxychloroquine sulfate tablets with plans to ramp up production to 50 million tablets, which could treat more than 1.5 million people. Mylan didn't mention anything about donating its product, but both chloroquine and hydroxychloroquine have been around for decades and are off-patent. Even if Mylan charges for its generic drug, the treatment is likely to be cheap. This won't move Mylan's financials much considering it registered $11.5 billion in revenue last year, and will only get bigger after its merger with Pfizer's (NYSE: PFE) Upjohn division.

While they're not going to make much profit with these moves, Bayer, Teva, and Mylan should certainly earn some goodwill and positive PR.

a person holding a sign: Caution Outbreak Alert sign on a door with a patient and doctor in background © Getty Images Caution Outbreak Alert sign on a door with a patient and doctor in background

At a White House Briefing on Friday, when asked about whether chloroquine had been approved by the Food and Drug Administration as a treatment for COVID-19, Anthony Fauci, the head of the National Institute of Allergy and Infectious Diseases replied, "The answer is no, and the evidence that you're talking about...is anecdotal evidence," according to Business Insider.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.

SPONSORED:

10 stocks we like better than Teva Pharmaceutical Industries

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Teva Pharmaceutical Industries wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of March 18, 2020

 

AdChoices
AdChoices

More from The Motley Fool

The Motley Fool
The Motley Fool
image beaconimage beaconimage beacon